Ablexis Appoints Sean Stevens, Ph.D., as Vice President, Research

Ablexis Appoints Sean Stevens, Ph.D., as Vice President, Research
Proven Expertise and Industry Experience Enhances Senior Management Team Focused on Developing Innovative, Next Generation Platform for Antibody Drug Discovery

SAN FRANCISCO--(BUSINESS WIRE)--Ablexis, LLC, a biotechnology company dedicated to developing the AlivaMab Mouse, an innovative next-generation platform for antibody drug discovery, announced today the appointment of Sean Stevens, Ph.D., as vice president, research. Reporting to Larry L. Green, Ph.D., chief executive officer of Ablexis, Dr. Stevens will lead the development and assist in the ongoing commercialization of the AlivaMab Mouse platform.

"We believe Sean joining Ablexis further solidifies our leadership team as one of the most experienced in the successful development and commercialization of innovative transgenic animal platforms for human therapeutic antibody discovery," said Dr. Green. "Sean's experiences and insights in building and using both novel transgenic mouse and in vitro platforms for therapeutic antibody discovery will be invaluable as we continue advancing our unique AlivaMab Mouse technology. I am very pleased to welcome Sean to the Ablexis team."

Dr. Stevens brings more than twenty years of experience in the fields of molecular immunology and B-cell biology, particularly as applied to the successful creation and utilization of transgenic mouse platforms for human therapeutic antibody drug discovery. He was a co-creator of the VelocImmune® Mouse at Regeneron, Inc., where he also identified therapeutic antibody drug targets, directed discovery and development programs for antibody drug candidates and built collaborative relationships with external corporate and academic partners. Most recently, he was with AnaptysBio, Inc., where he led a team involved in the development and application of an in vitro technology for creating human therapeutic antibodies. Dr. Stevens holds a Ph.D. in molecular biology from the University of Pennsylvania and performed his postdoctoral work at Rockefeller University.

Dr. Stevens also commented on his appointment: "I am thrilled to be joining Ablexis and working with this highly experienced leadership team. With Ablexis having just established a unique five-member pharmaceutical consortium based on licensing the AlivaMab Mouse technology, this is a very exciting time at the company. I am eager to begin applying my expertise and helping the company continue to meet its goals."

About Ablexis, LLC

Ablexis, LLC, was founded in December 2009 based on technology established by Aliva Biopharmaceuticals, Inc. Ablexis is developing the AlivaMab Mouse, an innovative, next-generation transgenic mouse platform intended to provide the foundation for the efficient discovery and development of the next wave of human therapeutic antibodies. In October 2010, Ablexis formed a five-member consortium made up of five of the top fifteen global pharmaceutical companies, granting each member non-exclusive licenses to the Ablexis AlivaMab Mouse technology. The company is based in San Francisco; more information can be found by visiting the company's website at www.ablexis.com.


Contacts
Pure Communications, Inc.
Dan Budwick, 973-271-6085
[email protected]

Suggested Articles

Minerva's seltorexant helped patients fall asleep more quickly and stay asleep for longer, beating placebo and Sanofi’s Ambien in a phase 2b study.

Cannabidiol might work as a powerful antibiotic against certain drug-resistant bacteria such as methicillin-resistant S. aureus.

Krystal Biotech posted data from a phase 2 study showing its topical gene therapy closed the majority of wounds in patients with a rare skin disorder.